Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Stock Sank Today

By Keith Speights - Mar 10, 2020 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech provided a disappointing Q4 update.

What happened

Shares of Akebia Therapeutics (AKBA -1.48%) were sinking today, down 11.1% as of 3:23 p.m. EDT, after dropping as much as 15.3% earlier in the session. The decline came after Akebia reported its 2019 fourth-quarter and full-year results before the market opened on Tuesday.

Akebia posted Q4 revenue of $69.6 million, below the consensus Wall Street estimate of $93.15 million. The company reported a net loss of $94.5 million, or $0.79 per share. The average analyst estimate was for a Q4 net loss of $0.47 per share. 

Black and white photo of two test tubes in a rack

Image source: Getty Images.

So what

Those top- and bottom-line misses really don't matter in the larger scheme of things. Nearly 60% of Akebia's revenue at this point comes from its collaboration deals.

The most important number for Akebia in its Q4 update was its cash position. The company reported cash, cash equivalents, and available-for-sale securities of $147.7 million as of Dec. 31, 2019. This should be sufficient to fund operations into 2021.

Now what

The future prospects for biotech stocks like Akebia Therapeutics are linked to their pipelines. Akebia plans to report results in the second quarter of this year from one of its late-stage studies of vadadustat in treating anemia due to chronic kidney disease, with results from another study to follow in mid-2020.

The company hopes to pick up a Priority Review Voucher from the FDA to expedite the review of the drug. If all goes well, Akebia's revenue should provide much better quarterly updates in 2021, after an anticipated commercial launch of vadadustat.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics, Inc. Stock Quote
Akebia Therapeutics, Inc.
$0.40 (-1.48%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.